




Treatment of TB

Lisa Armitige, MD, PhD
September 13, 2023

TB Intensive
September 13 – 15, 2023
Richmond, TX


1



Lisa Armitige, MD, PhD has the following disclosures to make:

- No conflict of interests
- No relevant financial relationships with any commercial companies pertaining to this educational activity

2



Treatment of Tuberculosis

Lisa Y. Armitige, MD, PhD
Co-Medical Director
Heartland National TB Center

Professor of Medicine and Pediatrics
University of Texas HSC at Tyler

TB Intensive
Fort Bend, TX
September 13, 2023

3



Clinical Infectious Diseases
IDSA GUIDELINE

IDSA
Infectious Diseases Society of America

hivma
hiv medicine association

OXFORD


Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children

David M. Lewinsohn,^{1,8} Michael K. Leonard,^{2,9} Philip A. LoBue,^{3,8} David L. Cohn,⁴ Charles L. Daley,⁵ Ed Desmond,⁶ Joseph Keane,⁷ Deborah A. Lewinsohn,¹ Ann M. Loeffler,⁸ Gerald H. Mazurek,³ Richard J. O'Brien,⁸ Madhukar Pai,¹⁰ Luca Richeldi,¹¹ Max Salfinger,¹² Thomas M. Shinnick,³ Timothy R. Sterling,¹³ David M. Warshauer,¹⁴ and Gail L. Woods¹⁵


¹Oregon Health & Science University, Portland, Oregon; ²Emory University School of Medicine and ³Centers for Disease Control and Prevention, Atlanta, Georgia; ⁴Denver Public Health Department, Denver, Colorado; ⁵National Jewish Health and the University of Colorado Denver; and ⁶California Department of Public Health, Richmond; ⁷St James's Hospital, Dublin, Ireland; ⁸Francis J. Curry International TB Center, San Francisco, California; ⁹Foundation for Innovative New Diagnostics, Geneva, Switzerland; ¹⁰McGill University and McGill International TB Centre, Montreal, Canada; ¹¹University of Southampton, United Kingdom; ¹²National Jewish Health, Denver, Colorado; ¹³Vanderbilt University School of Medicine, Vanderbilt Institute for Global Health, Nashville, Tennessee; ¹⁴Wisconsin State Laboratory of Hygiene, Madison; and ¹⁵University of Arkansas for Medical Sciences, Little Rock

Lewinsohn et al. CID. 2016

4



5




Sites of TB Disease

- Lungs

Extrapulmonary:

- Larynx
- Pleural effusion
- Kidneys
- Lymphatics
- Bones & joints
- Miliary (disseminated)



6

Signs & Symptoms Pulmonary TB

Pulmonary Symptoms:

- Productive prolonged cough of over 3 weeks duration
- Chest pain
- Hemoptysis

Systemic Symptoms:

- Fever
- Chills
- Night sweats
- Appetite loss
- Weight loss
- Easy fatigability

7

Evaluation for TB

- Medical history
- Physical examination
- Testing for TB infection
- Chest radiograph
- Bacteriologic or histologic exam

8

No CXR study shows findings specific for TB

Cavitary process are more likely to be TB

Common mimics of TB =


- Non-tuberculous mycobacteria (NTM)
- fungal infection
- bacterial abscesses
- necrotic neoplasm (especially lung neoplasm)

9

CXR – old healed TB

- Nodules & fibrotic lesions may contain slowly multiplying bacilli = potential for progression
- CXR consistent with old TB and + TST/IGRA = high priority for LTBI treatment

Calcified nodular lesions (calcified granuloma) pose a very low risk for future progression



10

Bacteriologic and Histologic Examinations

When lung or larynx is site of disease:

- 3 sputum specimens for AFB smear and culture
- Collected 8-24 hours apart with at least 1 early morning specimen



Specimens should be obtained in an isolated, well-ventilated area or sputum collection booth

13

Culture Yield




Figure 2. Proportion of subjects with cultures positive for *Mycobacterium tuberculosis*, by diagnostic technique, for 79 subjects with results for all 5 sputum samples obtained by induction with nebulized hypertonic saline (IS) and all 3 gastric washing (GW) specimens. Cumulative proportions are shown for the 5 IS samples. $P = .25$, by paired binomial probability test comparing diagnostic yield of all 5 IS samples versus 3 day 1 IS samples. *Bronchoalveolar lavage (BAL) culture results were available for 19 subjects.

Brown et al Clin Infect Dis 2007(44):1415

14

Bacteriologic and Histologic Examinations

Extrapulmonary Specimens

- Urine
- Cerebrospinal fluid *
- Pleural fluid *
- Pus
- Biopsy specimens

*recovery poor



15

Laboratory Examination

- AFB smear
- AFB culture
- Nucleic acid amplification test (NAAT)
 - GeneXpert
 - Molecular Detection of Drug Resistance (MDDR)

16

Treatment of Tuberculosis



17

Treatment of Culture-Positive Drug Susceptible Pulmonary TB



• General conclusions from the literature

- 6 mo (26 wk) is the **MINIMUM** duration of Rx
- 6 mo regimens require rifampin throughout and PZA for the first 2 months
- 6 mo regimens are effective without INH
- Intermittent regimens (2-3x/wk):
 - **GIVEN by DOT ONLY**
 - Drug susceptible isolate
 - Regimen contains INH and rifampin

18

Antituberculosis Drugs (ATS/CDC/IDSA)



- First-Line drugs (**RIPE**)
 - Isoniazid
 - Rifampin
 - Rifapentine
 - Rifabutin*
 - Ethambutol
 - Pyrazinamide
- *Not FDA approved for TB
- Second-Line Drugs
 - Cycloserine
 - Ethionamide
 - Levofloxacin*
 - Moxifloxacin*
 - PAS
 - Streptomycin
 - Amikacin/~~Kanamycin~~
 - ~~Capreomycin~~
 - Bedaquiline
 - Delamanid
 - Pretomanid

19

Treatment of Culture-Positive Drug Susceptible Pulmonary TB




- General conclusions from the literature:
 - Without PZA - minimum duration is 9 months
 - Without rifampin – see Dr. Seaworth's talk but, basically, treat like MDR
 - Streptomycin and ethambutol (EMB) are approximately equivalent in effect (BUT concern about increasing Streptomycin resistance among foreign born leads to preference of EMB for initial therapy)

20

ATS recommendations for treatment of tuberculosis

Table 2. Drug Regimens for Microbiologically Confirmed Pulmonary Tuberculosis Caused by Drug-Susceptible Organisms

Regimen	Drug ^a	Intensive Phase	Continuation Phase		Range of Total Doses	Comments ^{c,d}	Regimen Effectiveness
		Interval and Dose ^b (Minimum Duration)	Drugs	Interval and Dose ^{b,c} (Minimum Duration)			
1	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	7 d/wk for 126 doses (18 wk), or 5 d/wk for 90 doses (18 wk)	182–130	This is the preferred regimen for patients with newly diagnosed pulmonary tuberculosis.	 <p>Greater</p> <p>Lesser</p>
2	INH RIF PZA EMB	7 d/wk for 56 doses (8 wk), or 5 d/wk for 40 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	110–94	Preferred alternative regimen in situations in which more frequent DOT during continuation phase is difficult to achieve.	
3	INH RIF PZA EMB	3 times weekly for 24 doses (8 wk)	INH RIF	3 times weekly for 54 doses (18 wk)	78	Use regimen with caution in patients with HIV and/or cavitory disease. Missed doses can lead to treatment failure, relapse, and acquired drug resistance.	
4	INH RIF PZA EMB	7 d/wk for 14 doses then twice weekly for 12 doses ^a	INH RIF	Twice weekly for 36 doses (18 wk)	62	Do not use twice-weekly regimens in HIV-infected patients or patients with smear-positive and/or cavitory disease. If doses are missed, then therapy is equivalent to once weekly, which is inferior.	

21

Treatment for TB disease in Pregnancy

- A person diagnosed with or strongly suspected of having TB disease should be started on treatment without delay
- All first line drugs are generally considered safe in pregnancy
- Treatment regimen
 - PZA or no PZA?
 - Rifampin, INH, EMB for 9 months if PZA is excluded

22

Yes! You can X-ray a pregnant patient!



ACOG COMMITTEE OPINION

Number 723 • October 2017

(Replaces Committee Opinion Number 596, February 2010)

Committee on Obstetric Practice

This document is reviewed by the American College of Radiology and the American Institute of Ultrasound in Medicine. This Committee Opinion was developed by the American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Member contributions included Indira Capel, MD, Anne El-Sayed, MD, R. Philip Hines, MD, and Karen R. Williams, MD. This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Table 2. Effects of Gestational Age and Radiation Dose on Radiation-Induced Teratogenesis

Gestational Period	Effects	Estimated Threshold Dose*
Before implantation (0–2 weeks after fertilization)	Death of embryo or no consequence (all or none)	50–100 mGy
Organogenesis (2–8 weeks after fertilization)	Congenital anomalies (skeleton, eyes, genitalia)	200 mGy
	Growth restriction	200–250 mGy
Fetal period	Effects	Estimated Threshold Dose*
8–15 weeks	Severe intellectual disability (high risk) [†]	60–310 mGy
	Intellectual deficit	25 (10-point loss per 1,000 mGy)
	Microcephaly	200 mGy
16–25 weeks	Severe intellectual disability (low risk)	250–280 mGy*

*Data based on results of animal studies, epidemiologic studies of survivors of the atomic bombings in Japan, and studies of groups exposed to radiation for medical reasons (eg, radiation therapy for carcinoma of the breast).

[†]Because this is a period of rapid neuronal development and migration.

Modified from Patel SJ, Reade DL, Katz DS, Subramaniam R, Amorosa JK. Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. *Radiographics* 2007;27:1705–22.

Table 3. Fetal Radiation Doses Associated With Common Radiologic Examinations

Type of Examination	Fetal Dose* (mGy)
<i>Very low-dose examinations (<0.1 mGy)</i>	
Cervical spine radiography (anteroposterior and lateral views)	<0.001
Head or neck CT	0.001–0.01
Radiography of any extremity	<0.001
Mammography (two views)	0.001–0.01
Chest radiography (two views)	0.0005–0.01
<i>Low- to moderate-dose examinations (0.1–10 mGy)</i>	
Radiography	
Abdominal radiography	0.1–3.0
Lumbar spine radiography	1.0–10
Intravenous pyelography	5–10
Double-contrast barium enema	1.0–20
CT	
Chest CT or CT pulmonary angiography	0.01–0.66
Limited CT pelvimetry (single axial section through the femoral heads)	<1
Nuclear medicine	
Low-dose perfusion scintigraphy	0.1–0.5
Technetium-99m bone scintigraphy	4–5
Pulmonary digital subtraction angiography	0.5
<i>Higher-dose examinations (10–50 mGy)</i>	
Abdominal CT	1.3–35
Pelvic CT	10–50
¹⁸ F PET/CT whole-body scintigraphy	10–50

23

PZA in Pregnancy

- The WHO and IUATLD endorse use of PZA in the treatment of TB in pregnancy
- The CDC 2003 treatment guidelines did not endorse use of PZA in pregnancy due to lack of studies to show safety
- Current (2016) CDC/IDSA/ATS treatment guidelines state
 - Clinicians should evaluate risk/benefit of prescribing PZA, discuss with patient, informing patient that benefits may outweigh risk
 - Patients with HIV, extrapulmonary or severe disease should receive PZA in their treatment regimen

24

Suspected Active TB at Delivery

- Protect the delivery team
- Try to find a negative pressure room for delivery or perhaps a room further away from the general floor, like a surgical suite
- Delivery team should wear N95 masks
- Make arrangements to send placenta for pathologic evaluation and AFB culture



25

After-Delivery Concerns

- Should you separate the patient from their infant?
 - Only if the patient is suspected of having MDR TB
 - If patient is infectious, put the baby on INH or rifampin and have the patient wear a surgical mask while holding the baby until they are no longer infectious
- Can the patient breastfeed?
 - Yes
 - First line TB drugs all into the breastmilk in low but safe levels

26

Drug Penetration of CSF

Table 2. Anti-tuberculosis drugs used in TBM treatment [31–34,164].

Drug	Forms	Oral bio-availability (%)	Food effect	Plasma protein binding (%)	CNS penetration (%)
First-line					
Rifampicin	PO; IV	70	–30%	89	10–20
Isoniazid	PO; IV; IM	~100	–50% C_{max}	0–10	80–90
Pyrazinamide	PO	>90	None	~10	90–100
Ethambutol	PO	75–80	None	20–30	20–30
Rifabutin	PO	50	Decreased rate of absorption	85	50
Rifapentine	PO	70	None	98	–

Expert Review of Clinical Pharmacology, 12:3, 267-288

27

Drug Penetration of CSF

Table 2. Anti-tuberculosis drugs used in TBM treatment [31–34,164].

Drug	Forms	Oral bio-availability (%)	Food effect	Plasma protein binding (%)	CNS penetration (%)
First-line					
Rifampicin	PO; IV	70	–30%	89	10–20
Isoniazid	PO; IV; IM	~100	–50% C_{max}	0–10	80–90
Pyrazinamide	PO	>90	None	~10	90–100
Ethambutol	PO	75–80	None	20–30	20–30
Rifabutin	PO	50	Decreased rate of absorption	85	50
Rifapentine	PO	70	None	98	–

Expert Review of Clinical Pharmacology, 12:3, 267-288

28

Drug Penetration of CSF

Table 2. (Continued).


Drug	Forms	Oral bio-availability (%)	Food effect	Plasma protein binding (%)	CNS penetration (%)
Levofloxacin	PO; IV	~100	None	24–38	70–80
Moxifloxacin	PO; IV	90	None	50	70–80
Ethionamide	PO	~100	None	~30	80–90
Cycloserine	PO	65–90	Slight decrease	~0	80–90

Drug	Forms	Oral bio-availability (%)	Food effect	Plasma protein binding (%)	CNS penetration (%)
Linezolid	PO; IV	~100	–23% with high-fat meals	31	70
Bedaquiline	PO	Unknown	Increase	>99	Likely poor (limited data)
Delamanid	PO	25–47	Increase	>99	No human data
Pretomanid	PO	Unknown	Increase	93	No human data


Expert Review of Clinical Pharmacology, 12:3, 267-288

29

Intensified Regimen for TBM (Adults)




N Engl J Med 2016;374:124-34.



Lancet Infect Dis 2013; 13: 27–35

30



31

TB Drugs Cleared by the Kidneys

- Ethambutol (EMB)
- Pyrazinamide (PZA)
- Levofloxacin
- Cycloserine
- Anything that is injected
 - Streptomycin
 - Amikacin
 - Capreomycin
 - Kanamycin

32

Treatment Regimen: Active TB with renal insufficiency

- Renal insufficiency counted at CrCl <30
- Initial Phase (first two months):
 - INH 300mg po daily
 - Rifampin 600mg po daily
 - Ethambutol 15-25mg/kg po *thrice weekly*
 - PZA 25-35mg/kg po *thrice weekly*
 - Vitamin B6 50mg daily
- Continuation
 - INH and Rifampin x 4 – 7 months

33

Hepatotoxicity – What to do about it

- First, can you stop medications safely?
 - Is the patient really sick (ICU, septic sick)?
 - Does he have a form of TB you really don't want going untreated (disseminated disease, meningitis, associated with HIV or poorly controlled diabetes)?
- If the patient is ill, pick something liver-sparing and continue treatment.
- If the patient is stable, stop the medications until the liver cools off and do a drug challenge.

34

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active TB

(Yee, AJRCCM 2003; 167: 1472)




- PZA: 1.48/100 person months of exposure
- INH: 0.49/100 person months
- Rif : 0.43/100 person months
- EMB: 0.07/100 person months

"The drug most likely responsible for the occurrence of hepatitis or rash during therapy for active TB is PZA"


35

So, what is
'liver-friendly/sparing'?




36

What if they are really, really sick.....?

- 
- | | | |
|----------------------|---|------------------------------|
| • INH | | • Liver |
| • Rifampin | | • Liver |
| • Rifabutin | | • Liver/kidney |
| • Ethambutol (EMB) | | • Kidney |
| • Pyrazinamide (PZA) | | • Kidney (liver metabolites) |
| • Moxifloxacin | ← | • Liver, but..... |
| • Levofloxacin | | • Kidney |
| • Amikacin | ← | • Kidney |
| • Linezolid | ← | • Neither liver or kidney |


37

Liver sparing but not dying

- 
- | | | |
|----------------------|---|------------------------------|
| • INH | | • Liver |
| • Rifampin | | • Liver |
| • Rifabutin | | • Liver/kidney |
| • Ethambutol (EMB) | ← | • Kidney |
| • Pyrazinamide (PZA) | | • Kidney (liver metabolites) |
| • Moxifloxacin | ← | • Liver, but..... |
| • Levofloxacin | | • Kidney |
| • Amikacin | | • Kidney |
| • Linezolid | ← | • Neither liver or kidney |


38

Liver-friendly

- 
- | | | |
|----------------------|---|------------------------------|
| • INH | | • Liver |
| • Rifampin | ← | • Liver |
| • Rifabutin | | • Liver/kidney |
| • Ethambutol (EMB) | ← | • Kidney |
| • Pyrazinamide (PZA) | | • Kidney (liver metabolites) |
| • Moxifloxacin | ← | • Liver, but..... |
| • Levofloxacin | | • Kidney |
| • Amikacin | | • Kidney |
| • Linezolid | | • Neither liver or kidney |

39

What is a proper 'drug challenge'?

- 
- Stop the medications. Cool the patient off.
 - When LFTs have returned to < 2 times the ULN, you are ready to challenge
 - Start with rifampin and ethambutol, then INH (or moxifloxacin if there is a shortage....), then strongly consider whether you need PZA
 - Wait 3-7 days between additions
 - Check LFTs before starting the next drug (and wait for the results, please)
 - If LFTs rise stop the last drug added and go to the next

40

Smear Negative Pulmonary TB



- Sputum has been collected and has resulted smear and culture negative
- Treatment recommendations are for RIPE x 2 months, then RI for 2 more months
- Consider leaving all 4 drugs or at least INH/rifampin/EMB

41

M. bovis



- Unpasteurized milk products
 - Travel, gifts from foreign places
- Bladder instillation with BCG
 - Fever, **sterile pyuria**!
- **Resistant to PZA**, susceptible to INH, rifampin and EMB
 - Note: PZA monoresistance likely *M. bovis* or *M. kansasii*

42

Management of Treatment Interruptions

- Initial phase of therapy
 - <14 days –complete standard # of doses
 - >14 days – restart from the beginning
- Continuation phase
 - >80% doses by DOT – if initial smear negative, may stop
 - Repeat culture
 - >3 month interruption restart from beginning
 - <3 month interruption, culture positive, restart
 - <3 month interruption, culture negative, give an additional 4 months


43

Relapsed Tuberculosis

- Most relapses occur within the first 6 – 12 months after stopping therapy but some occur 5 or more years later
- Nearly all drug susceptible patients who were treated with a rifamycin and received DOT will relapse with drug susceptible organisms
 - Treat with standard RIPE regimen
- Patients with a history of poor adherence, self administration or self administration should have additional sputum collected and careful selection of a treatment regimen


44

Medical Factors Associated With Relapse of Tuberculosis

- 
- Cavitory TB
 - Extensive disease on CXR; bilateral infiltrates
 - Positive 2 month culture
 - Associated medical conditions
 - Diabetes
 - HIV
 - Malabsorption of TB drugs
 - Tuberculous lymphadenitis
 - Underweight at diagnosis and failure to gain
 - Drug resistant disease
 - Prior treatment for tuberculosis

45

TB Elderly

- 
- Hepatotoxicity and as well as other medication toxicities are more common
 - May want to weight the risk/benefit of using PZA

46

Criteria to Be Considered Noninfectious

Patients no longer considered infectious if:

- 3 consecutive negative sputum smears
 - collected at least 8 hours apart
 - one early morning specimen
- Their symptoms have improved, AND
- Adhering to **adequate** treatment regimen ≥ 2 weeks (one week if smear negative to start)
 - DOT – YES!
 - Do you know drug susceptibilities?



47

Treatment shortening regimen – Drug Sensitive TB

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

S.E. Dorman, P. Nahid, E.V. Kurbatova, P.P.J. Phillips, K. Bryant, K.E. Dooley, M. Engle, S.V. Goldberg, H.T.T. Phan, J. Hakim, J.L. Johnson, M. Lourens, N.A. Martinson, G. Muzanyi, K. Narunsky, S. Nerette, N.V. Nguyen, T.H. Pham, S. Pierre, A.E. Purfield, W. Samaneka, R.M. Savic, I. Sanne, N.A. Scott, J. Shenje, E. Sizemore, A. Vernon, Z. Waja, M. Weiner, S. Swindells, and R.E. Chaisson, for the AIDS Clinical Trials Group and the Tuberculosis Trials Consortium

2234 participants (194 PLHIV, 1703 with cavity on CXR)
Randomized 1:1:1 to 3 arms
Noninferiority study


N Engl J Med 2021;384:1705-18.

48


Study 31/A5349




Control
(2HRZE/4HR)



RPT
(2HPZE/2HP)



Control
(2HPZM/4HPM)




Notes:

- HRZE dosed at standard doses
- Dosed daily, 7 days/week, observed 5 days/week
- Rifapentine 1200 mg (8 tablets)
- Moxifloxacin 400 mg


49

Study 31 - Results



50

Challenges associated with shorter treatment regimens

- 
- Pill burden
 - Tolerability (versus safety, efficacy)
 - Familiarity with the regimen
 - Drug shortages (first rifapentine, now INH)

51

Questions?

Lisa.Armitige@dshs.texas.gov

Or

1-800-TEX-LUNG

52